Priority 3 from the Miscarriage PSP
| UNCERTAINTY: What investigations are of true clinical value? (e.g. ultrasound, gene sequencing, natural killer cells, thromboelastography (TEG), microarray testing of the fetus, paternal investigations, plasminogen activator inhibitor polymorphism) (JLA PSP Priority 3) | |
|---|---|
| Overall ranking | 3 |
| JLA question ID | 0053/3 |
| Explanatory note | Examples of original survey submissions: Could the risk of miscarriage be identified earlier using biological markers, either in early pregnancy or pre-conception?; Usefulness of plasminogen activator inhibitor 4G/5G polymorphism testing in recurrent miscarriage ; Further research on testing of expelled tissue?; Why the fathers are not investigated to see if there is a cause for repeated miscarriage |
| Evidence |
None identified |
| Health Research Classification System category | Reproduction |
| Extra information provided by this PSP | |
|---|---|
| Submitted by | 10 professionals ~ 44 women |
| PSP information | |
|---|---|
| PSP unique ID | 0053 |
| PSP name | Miscarriage |
| Total number of uncertainties identified by this PSP. | 58 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website) |
| Date of priority setting workshop | 14 October 2016 |